Table 3 Comparison of the clinicopathological features between SC (+) and SC (−) + SNC
From: Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR
Total n = 118 | SC (+) (n = 13) | SC (−) + SNC (n = 105) | P valuesa |
|---|---|---|---|
Age (range) | 73 (53—83) | 68 (37—87) | 0.711b |
Male | 7 (53.8%) | 62 (59.0%) | 0.711 |
Current or ex-smoker | 11 (84.6%) | 72 (68.6%) | 0.340 |
Right side | 9 (69.2%) | 58 (55.2%) | 0.389 |
Lobe | Â | Â | Â |
Upper | 4 (30.8%) | 62 (59.1%) | Â |
Middle | 0 | 6 (5.7%) | Â |
Lower | 9 (69.2%) | 37 (35.2%) | 0.675 |
Emphysema | 1 (7.7%) | 11 (10.5%) | 1.000 |
Interstitial pneumonia | 1 (7.7%) | 1 (1.0%) | 0.209 |
Tumor size (mm) (range) | 37 (21—98) | 22 (9—54) |  < 0.001b |
PET SUVmax (range) | 7.4 (3.0—19.4) | 2.3 (0—30) |  < 0.001b |
Clinical stage (8th edition) | Â | Â | 0.011 |
cStage I | 6 (46.2%) | 83 (79.0%) | |
cStage II | 4 (30.7%) | 17 (16.2%) | |
cStage III | 3 (23.1%) | 5 (4.8%) | |
Pathological stage | Â | Â | Â |
pStage 0, I | 4 (30.8%) | 82 (78.1%) | Â |
pStage II | 3 (23.1%) | 8 (7.6%) | Â |
pStage III | 5 (38.4%) | 12 (11.4%) | Â |
pStage IV | 1 (7.7%) | 3 (2.9%) | 0.002 |
Lymphatic invasion | 2 (16.7%) | 19 (18.3%) | 1.000 |
Vascular invasion | 6 (50.0%) | 31 (29.8%) | 0.191 |
Pleural invasion | 4 (33.3%) | 27 (26.0%) | 0.487 |
Existence of STAS | 12 (92.3%) | 36 (34.3%) |  < 0.001 |
EGFR status in FFPE | Â | Â | Â |
Ex18 | 0 | 4 (3.8%) | Â |
Ex19 | 2 (15.4%) | 25 (23.8%) | Â |
Ex20 | 0 | 4 (3.8%) | Â |
Ex21 | 3 (23.1%) | 26 (24.8%) | Â |
Wild-type | 8 (61.5%) | 46 (43.8%) | 0.902 |